Viatris Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Viatris is gedaald met een gemiddeld jaarlijks percentage van -27.3%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks groeide met 10.3%. De inkomsten zijn daalde met een gemiddeld percentage van 1.7% per jaar.
Belangrijke informatie
-27.26%
Groei van de winst
-19.79%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 5.95% |
| Inkomstengroei | -1.71% |
| Rendement op eigen vermogen | -23.89% |
| Nettomarge | -24.58% |
| Volgende winstupdate | 07 May 2026 |
Recente prestatie-updates uit het verleden
Recent updates
VTRS: Cost Savings And FY26 Outlook Will Shape Balanced Re Rating Potential
Narrative Update on Viatris Analysts have lifted their price targets on Viatris by $2 to $3 into a range that now includes $20, citing achieved cost savings, FY26 guidance above consensus and expectations that ongoing efficiency efforts could support earnings growth and a modestly lower future P/E assumption of around 17x. Analyst Commentary Street research on Viatris has centered on the recent cost-saving progress, updated FY26 outlook and what that could mean for valuation, especially around a P/E assumption near 17x.VTRS: Cost Savings And FY26 Outlook Will Drive Re Rating Potential
Analysts recently lifted their price target on Viatris by $2, reflected in an updated fair value view of $15.72, citing the company’s cost-saving progress, higher long term profit margin assumptions, and a lower future P/E multiple as key supports for the revised outlook. Analyst Commentary Recent research on Viatris has centered on cost savings, margin objectives, and capital allocation, with several firms adjusting price targets higher and, in some cases, upgrading ratings.
VTRS: Cost Savings And Capital Returns Will Support Future Upside Potential
Analysts have raised the fair value estimate for Viatris to $20 from $16, citing completed cost savings, guidance that is above prior consensus, and expectations for mid single digit revenue growth with higher profit margins, which support a lower future P/E assumption. Analyst Commentary Bullish analysts have been leaning more constructive on Viatris, with several price target increases and upgrades pointing to growing confidence in the company’s execution on cost savings and its guidance.Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan?
Mar 20
VTRS: FY26 Guidance And Cost Savings Will Test Rich Earnings Expectations
Analysts have lifted their price target on Viatris by $2 to $20, citing the company hitting recent cost saving goals, issuing FY26 guidance above consensus, and outlining a path toward revenue and earnings growth. They believe this could support a lower future P/E multiple.VTRS: Affordable Medicines Focus And Pipeline Progress Will Face Execution Risk
Analysts have lifted their price target on Viatris by about $1.44, reflecting updated assumptions around fair value, modestly higher revenue growth and margins, and a slightly richer future P/E multiple in line with recent positive research commentary. Analyst Commentary Recent research on Viatris has tilted more constructive, with several firms adjusting ratings and price targets higher.VTRS: Capital Returns And Affordable Medicines Focus Will Drive Upside Potential
Analysts have raised their price expectations for Viatris to $16, supported by recent target increases related to the affordable medicines theme and a slightly adjusted outlook for discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Viatris has leaned more constructive, with several bullish analysts lifting price targets and upgrading their views.VTRS: Capital Returns And Affordable Medicines Theme Will Support Upside Potential
Narrative Update: Viatris Analysts have lifted their price target on Viatris to US$16 from US$14, citing a slightly lower discount rate, updated assumptions for modestly higher revenue growth, a recalibrated profit margin outlook, and a higher future P/E multiple supported by recent research highlighting expected buybacks, debt reduction, and continued interest in the affordable medicines theme heading into 2026. Analyst Commentary Bullish analysts are leaning into a more constructive view on Viatris, pointing to capital allocation plans and the appeal of the affordable medicines theme as key supports for the current investment case.VTRS: Affordable Medicines Theme And Pipeline Milestones Will Support Future Cash Returns
Analysts have nudged their price target on Viatris higher from US$15 to US$16, citing continued interest in the affordable medicines theme heading into 2026 as a key support for the updated fair value estimate of about US$12.67 and a slightly higher implied future P/E of about 35.55x. Analyst Commentary Recent research on Viatris has centered on the updated US$16 price target and how it lines up with the affordable medicines theme, the implied fair value of about US$12.67, and the higher future P/E of roughly 35.55x.VTRS: Future Cash Returns And Pipeline Milestones Will Support Steady Share Performance
Analysts have nudged their price target on Viatris slightly higher to reflect a modestly improved outlook for long term earnings quality and valuation, in line with a broader pattern of upward target revisions across comparable income oriented names. Analyst Commentary Bullish analysts view the latest price target increase as confirmation that Viatris is gradually rebuilding credibility on earnings durability, with improving visibility on cash flow supporting a higher fair value range.VTRS: Cash Returns And Margin Discipline Will Support Steadier Share Performance
Analysts have nudged their price target on Viatris modestly higher, lifting fair value by about $0.32 to approximately $12.44 as they factor in a slightly lower discount rate, steady revenue growth expectations, and marginally improved long term profitability and valuation assumptions. Analyst Commentary Bullish analysts point to the modestly higher fair value estimate as evidence that Viatris is executing consistently against expectations, with incremental improvements in long term profitability assumptions supporting a more constructive stance on the shares.VTRS: Share Buyback And Cost Discipline Will Drive Positive Momentum Ahead
Analysts have maintained Viatris's fair value estimate at $12.13 per share. They cite continued expectations for stable revenue growth, consistent profit margins, and marginally increased discount rates in their updated models.VTRS: Operational Discipline And Asset Management Will Guide Balanced Outlook Ahead
The analyst price target for Viatris was increased slightly from $12.00 to $12.13, as analysts cited improved revenue growth and higher profit margin expectations as key factors for the adjustment. Analyst Commentary Recent analyst opinions on Viatris reflect a balance between improving financial outlook and continued areas of caution.VTRS: Accelerating Product Launches Will Benefit From Senior Healthcare Demand Growth
Analysts have raised their price target for Viatris from $11.88 to $12.00. They cite slightly improved revenue growth assumptions and a marginally lower discount rate in their updated models.Aging Populations And Asia Markets Will Unlock Future Value
Viatris's analyst price target has increased modestly from $11.43 to $11.88. Analysts cite incremental improvements in revenue growth prospects and ongoing adjustments to sector models.Aging Populations And Asia Markets Will Unlock Future Value
The consensus price target for Viatris has seen a marginal increase, primarily reflecting a slight improvement in revenue growth forecasts, resulting in a modest rise in fair value from $11.29 to $11.43. What's in the News FDA approved Viatris' Iron Sucrose Injection, USP, the first generic version of Venofer, for iron deficiency anemia in CKD patients, with Competitive Generic Therapy designation and 180 days of shared exclusivity.
New Product Launches And Expense Savings Will Strengthen Future Operations
New product launches and late-stage developments are expected to drive future revenue growth and improve net margins through higher-margin innovations.Viatris: One Swallow Doesn't Make A Summer
Feb 27Viatris: Consolidate In 2025, Win In 2026 - How 'Phase 2' Of Business Plan May Play Out
Jan 24Viatris: Looking At High Free Cash Flow Yield As Business Stabilizes
Jan 06Bargain Priced Viatris Reports Strong Q3 Earnings Results
Nov 08Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy
Oct 22Opbrengsten en kosten
Opbrengsten en kosten
Hoe Viatris geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 31 Dec 25 | 14,300 | -3,515 | 3,469 | 953 |
| 30 Sep 25 | 14,124 | -3,691 | 3,330 | 885 |
| 30 Jun 25 | 14,116 | -3,468 | 3,390 | 838 |
| 31 Mar 25 | 14,330 | -3,790 | 3,470 | 826 |
| 31 Dec 24 | 14,739 | -634 | 3,725 | 806 |
| 30 Sep 24 | 15,049 | -883 | 3,735 | 802 |
| 30 Jun 24 | 15,239 | -646 | 3,776 | 815 |
| 31 Mar 24 | 15,361 | -56 | 3,805 | 819 |
| 31 Dec 23 | 15,427 | 55 | 3,776 | 802 |
| 30 Sep 23 | 15,466 | 1,832 | 3,720 | 782 |
| 30 Jun 23 | 15,602 | 1,854 | 3,686 | 746 |
| 31 Mar 23 | 15,800 | 1,904 | 3,580 | 700 |
| 31 Dec 22 | 16,263 | 2,079 | 3,518 | 661 |
| 30 Sep 22 | 16,728 | 804 | 3,584 | 675 |
| 30 Jun 22 | 17,187 | 761 | 3,678 | 649 |
| 31 Mar 22 | 17,648 | 168 | 4,101 | 641 |
| 31 Dec 21 | 17,886 | -1,269 | 4,245 | 668 |
| 30 Sep 21 | 17,168 | -1,921 | 4,802 | 625 |
| 30 Jun 21 | 15,604 | -2,047 | 4,382 | 603 |
| 31 Mar 21 | 13,757 | -1,728 | 3,686 | 565 |
| 31 Dec 20 | 11,946 | -670 | 2,686 | 508 |
| 30 Sep 20 | 11,514 | 266 | 2,445 | 486 |
| 30 Jun 20 | 11,504 | 271 | 2,427 | 487 |
| 31 Mar 20 | 11,624 | 63 | 2,503 | 492 |
| 31 Dec 19 | 11,501 | 17 | 2,503 | 519 |
| 30 Sep 19 | 11,387 | 48 | 2,445 | 519 |
| 30 Jun 19 | 11,288 | 34 | 2,452 | 532 |
| 31 Mar 19 | 11,245 | 240 | 2,378 | 568 |
| 31 Dec 18 | 11,434 | 353 | 2,397 | 586 |
| 30 Sep 18 | 11,594 | 546 | 2,303 | 622 |
| 30 Jun 18 | 11,719 | 457 | 2,385 | 648 |
| 31 Mar 18 | 11,873 | 717 | 2,435 | 663 |
| 31 Dec 17 | 11,908 | 696 | 2,564 | 666 |
| 30 Sep 17 | 11,937 | 869 | 2,357 | 655 |
| 30 Jun 17 | 12,007 | 661 | 2,356 | 665 |
| 31 Mar 17 | 11,605 | 533 | 2,300 | 663 |
| 31 Dec 16 | 11,077 | 480 | 2,351 | 698 |
| 30 Sep 16 | 10,300 | 257 | 2,150 | 691 |
| 30 Jun 16 | 9,938 | 806 | 2,019 | 688 |
| 31 Mar 16 | 9,749 | 805 | 1,973 | 687 |
| 31 Dec 15 | 9,429 | 848 | 1,924 | 652 |
| 30 Sep 15 | 9,021 | 842 | 1,885 | 645 |
| 30 Jun 15 | 8,410 | 913 | 1,767 | 628 |
Kwaliteitswinsten: VTRS is momenteel verliesgevend.
Groeiende winstmarge: VTRS is momenteel verliesgevend.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: VTRS is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 27.3% per jaar.
Versnelling van de groei: Het is niet mogelijk om de winstgroei van VTRS over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.
Winst versus industrie: VTRS is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( -3.2% ).
Rendement op eigen vermogen
Hoge ROE: VTRS heeft een negatief Return on Equity ( -23.89% ), omdat het momenteel verliesgevend is.
Rendement op activa
Rendement op geïnvesteerd vermogen
Ontdek sterk presterende bedrijven uit het verleden
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/04/30 16:55 |
| Aandelenkoers aan het einde van de dag | 2026/04/29 00:00 |
| Inkomsten | 2025/12/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Viatris Inc. wordt gevolgd door 31 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Glen Santangelo | Barclays |
| Aaron Gal | Bernstein |